Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of β-lactam therapy in ESBL-producing Enterobacteriaceae infections
KCT0001895Phase 4Completed
- Sponsor
- Ministry of Health & Welfare
- Start
- Jan 2013
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ertapenem, cefepime and piperacillin + tazobactam in urinary tract infection (UTI) and extended-spectrum beta-lactamase-producing Enterobacterales infection, sponsored by Ministry of Health & Welfare. Started Jan 2013; status: completed.
02
Drugs
ertapenemcefepimepiperacillin + tazobactam
03
Conditions
urinary tract infection (UTI)extended-spectrum beta-lactamase-producing Enterobacterales infection
Beyond the preview
Go deeper on KCT0001895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001895.